The Bifidogenic Growth Stimulator Inhibits the Growth and Respiration of Helicobacter pylori

Background:  Triple therapy with amoxicillin, clarithromycin, and a proton‐pump inhibitor is a common therapeutic strategy for the eradication of Helicobacter pylori (H. pylori). However, frequent appearance of clarithromycin‐resistant strains is a therapeutic challenge. While various quinones are known to specifically inhibit the growth of H. pylori, the quinone 1,4‐dihydroxy‐2‐naphthoic acid (DHNA) produced by Propionibacterium has strong stimulating effect on Bifidobacterium. We were interested to see whether DHNA could inhibit the growth of H. pylori in in vitro or in vivo experimental setting.

[1]  T. Dairi.  [Alternative menaquinone biosynthetic pathway operating in microorganisms]. , 2009, Seikagaku. The Journal of Japanese Biochemical Society.

[2]  Jun Ishikawa,et al.  An Alternative Menaquinone Biosynthetic Pathway Operating in Microorganisms , 2008, Science.

[3]  K. Haruma,et al.  Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005 , 2007, Journal of Clinical Microbiology.

[4]  M. Taniguchi,et al.  Production of extracellular bifidogenic growth stimulator by anaerobic and aerobic cultivations of several propionibacterial strains. , 2007, Journal of bioscience and bioengineering.

[5]  K. Nagata,et al.  Idebenone Acts against Growth of Helicobacter pylori by Inhibiting Its Respiration , 2006, Antimicrobial Agents and Chemotherapy.

[6]  H. Koga,et al.  Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. , 2006, Nutrition.

[7]  S. Miura,et al.  Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing , 2005, Gut.

[8]  Geun Ho Kang,et al.  Impact of Clarithromycin Resistance on Eradication of Helicobacter pylori in Infected Adults , 2005, Antimicrobial Agents and Chemotherapy.

[9]  Robert J. Maier,et al.  An NADPH Quinone Reductase of Helicobacter pylori Plays an Important Role in Oxidative Stress Resistance and Host Colonization , 2004, Infection and Immunity.

[10]  M. Fujino,et al.  L-Serine, D- and L-proline and alanine as respiratory substrates of Helicobacter pylori: correlation between in vitro and in vivo amino acid levels. , 2003, Microbiology.

[11]  K. Murakami,et al.  Eradication rates of clarithromycin‐resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin , 2002, Alimentary pharmacology & therapeutics.

[12]  K. Kano,et al.  2-Amino-3-carboxy-1,4-naphthoquinone affects the end-product profile of bifidobacteria through the mediated oxidation of NAD(P)H , 2002, Applied Microbiology and Biotechnology.

[13]  N. Yoda,et al.  Effect of Ingested Culture of Propionibacterium freudenreichii ET-3 on Fecal Microflora and Stool Frequency in Healthy Females , 2002 .

[14]  L. Girard,et al.  Failure of Helicobacter pylori eradication: is poor compliance the main cause? , 2002, Gastroenterologie clinique et biologique.

[15]  N. Yoda,et al.  Isolation and Identification of a New Bifidogenic Growth Stimulator Produced by Propionibacterium freudenreichii ET-3 , 2002, Bioscience, biotechnology, and biochemistry.

[16]  R. P. Blankfield,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[17]  K. Sugano,et al.  Guidelines in the Management of Helicobacter pylori Infection in Japan , 2001, Helicobacter.

[18]  K. Nagata,et al.  Inhibitory Activities of Lansoprazole against Respiration in Helicobacter pylori , 2001, Antimicrobial Agents and Chemotherapy.

[19]  R. Poole,et al.  Microaerobic Physiology: Aerobic Respiration, Anaerobic Respiration, and Carbon Dioxide Metabolism , 2001 .

[20]  A. Munnich,et al.  Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study , 1999, The Lancet.

[21]  R. Poole,et al.  Microbial ubiquinones: multiple roles in respiration, gene regulation and oxidative stress management. , 1999, Microbiology.

[22]  T. Alarcón,et al.  Antibiotic resistance problems with Helicobacter pylori. , 1999, International journal of antimicrobial agents.

[23]  H. Kurihara,et al.  Effects of Culture-Powder of Propionibacterium freudenreichii ET-3 on Fecal Microflora of Normal Adults , 1999 .

[24]  J. Christodoulou,et al.  Respiratory chain complex III deficiency with pruritus: A novel vitamin responsive clinical feature , 1999 .

[25]  J. Christodoulou,et al.  Respiratory chain complex III [correction of complex] in deficiency with pruritus: a novel vitamin responsive clinical feature. , 1999, The Journal of pediatrics.

[26]  K. Kano,et al.  Mechanistic study on the roles of a bifidogenetic growth stimulator based on physicochemical characterization. , 1998, Biochimica et biophysica acta.

[27]  J. Koyama,et al.  Antimicrobial Activity of Novel Furanonaphthoquinone Analogs , 1998, Antimicrobial Agents and Chemotherapy.

[28]  H. Sato,et al.  Isolation and structural identification of bifidogenic growth stimulator produced by Propionibacterium freudenreichii. , 1997, Journal of dairy science.

[29]  K. Nagata,et al.  A cb-type cytochrome-c oxidase terminates the respiratory chain in Helicobacter pylori. , 1996, Microbiology.

[30]  R. Poole,et al.  The respiratory chain of Helicobacter pylori: identification of cytochromes and the effects of oxygen on cytochrome and menaquinone levels. , 1996, FEMS microbiology letters.

[31]  P. Benefield,et al.  Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. , 1994, Drugs & aging.

[32]  S. Meguro,et al.  Growth stimulator for bifidobacteria produced by Propionibacterium freudenreichii and several intestinal bacteria. , 1994, Journal of dairy science.

[33]  P D Klein,et al.  Effect of Treatment of Helicobacter pylori Infection on the Long-term Recurrence of Gastric or Duodenal Ulcer , 1992, Annals of Internal Medicine.

[34]  G. Friedman,et al.  Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.

[35]  I. Zs.-Nagy.  Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review. , 1990 .

[36]  G. Tytgat,et al.  Cure of duodenal ulcer associated with eradication of Helicobacter pylori , 1990, The Lancet.

[37]  M. Blaser.  Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. , 1990, The Journal of infectious diseases.

[38]  C. W. Moss,et al.  Isoprenoid quinones of Campylobacter cryaerophila, C. cinaedi, C. fennelliae, C. hyointestinalis, C. pylori, and "C. upsaliensis" , 1990, Journal of clinical microbiology.

[39]  I. Zs -Nagy.  Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review. , 1990, Archives of gerontology and geriatrics.

[40]  N. Tolbert,et al.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. , 1978, Analytical biochemistry.

[41]  R. L. Taylor,et al.  Guidelines for management , 1972 .